Tagrisso Approved as Adjuvant Therapy for Early-Stage EGFR-Mutant NSCLC
The approval was based on data from the double-blind, placebo-controlled phase 3 ADAURA study.
The approval was based on data from the double-blind, placebo-controlled phase 3 ADAURA study.
Increased risks persist beyond six months for patients with lung cancer receiving PD1i and with malignant melanoma receiving CTLA-4i.
Mutation frequencies of EGFR and KRAS were 30 and 10 percent, respectively, and 23 and 13 percent, respectively, for Mexican and Colombian patients.
As this research finds that many patients are distressed enough to require some form of intervention, a number of stress-reduction techniques are provided that can be easily put into practice.
Therapy-related AML after lung cancer is rare, but is associated with poor prognosis.
The approval was based on data from several clinical trials, including the phase 3 PACIFIC trial and the phase 3 CASPIAN trial.
Interim analysis shows risk for disease progression or death lower for first-line therapy with lorlatinib versus crizotinib.
Nicotine e-cigarettes added to counseling improved abstinence at 12 weeks, but not at 24 weeks.
Potential years of life lost per death highest for deaths due to cancers of testis, bones/joints, other endocrine sites.
Mortality reduced for patients with newly diagnosed breast, colorectal, lung cancers, mediated by earlier stage of diagnosis.